Tel:+86-027-59403931 Ext 8009 
Email: wwqin@oryzogen.com
Contact Us
Inquiry Now 
Tags
ListA total of 2 articles were found
-
Olbumin® receives approval to initiate Phase III Clinical Trials in US
Recently, Healthgen’s proprietary, first-in-class drug, Recombinant Human Albumin Injection (Oryza Sativa), successfully has successfully completed a Type C meeting with the U.S. FDA. During the meeting, Healthg...
Category: NEWS -
Clinical Trial Data of Recombinant Human Albumin Injection (Oryza Sativa) was published in the journal “Gut”
Source：Posted by Themecurve| Time：2025 Clinical Trial Data of Recombinant Human Albumin Injection (Oryza Sativa) was published in the journal "Gut" Source：Posted by Themecurve| Time：2025 Key Findings of the cl...
Category: NEWS